Patents by Inventor Cecile Morales

Cecile Morales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
    Patent number: 9101609
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: August 11, 2015
    Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip Tan, Sandy A Simon, Charles G Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A Ledbetter, Martha S Hayden-Ledbetter, Peter A Thompson, Cecile Morales
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20140086903
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 27, 2014
    Inventors: Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
  • CD3 IMMUNOTHERAPEUTICS AND USES THEREOF
    Publication number: 20130195850
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: November 15, 2012
    Publication date: August 1, 2013
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip TAN, Sandy Alexander SIMON, Charles G. CERVENY, Christy Anne NILSSON, William BRADY, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Peter Armstrong THOMPSON, Cecile MORALES
  • CD37 immunotherapeutics and uses thereof
    Patent number: 8333966
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Grant
    Filed: April 11, 2009
    Date of Patent: December 18, 2012
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Philip Tan, Sandy Alexander Simon, William Brady, Cecile Morales
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20110171208
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 11, 2009
    Publication date: July 14, 2011
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Philip Tan, Sandy Alexander Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Peter Armstrong Thompson, Cecile Morales
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20090274692
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 13, 2009
    Publication date: November 5, 2009
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Phillip Tan, Sandy A. Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter, Peter A. Thompson, Cecile Morales